DAPA-HF Update—Have We Lost SGLT2 Inhibitors to Cardiologists?!
In this medfyle
Expert Commentary by Prof. Francesco Giorgino, MD
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the ADA 2020 - 80th Scientific Sessions and presented by:
John J.V. McMurray, OBE, BSc (Hons), MB, ChB (Hons), MD, FRCP, FESC
BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
Mikhail N. Kosiborod, MD
Saint Luke’s Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO, USA
Silvio E. Inzucchi, MD
Section of Endocrinology, Yale University School of Medicine, New Haven, CT, USA
Jeffrey M. Testani, MD, MTR
Division of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, USA
The content is produced by Infomedica, the official reporting partner of ADA 2020 Virtual Meeting. The summary text was drafted by Patrick Moore, PhD, and reviewed by Marco Gallo, MD, an independent external expert, and approved by Dana M. Dabelea, MD, PhD, the scientific editor of the program.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Prof. Francesco Giorgino, MD
President, Italian Society of Endocrinology (SIE)
Professor of Endocrinology, Chairman, Department of Emergency and Organ Transplantation
Head, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases
University of Bari Aldo Moro
Chief, Division of Endocrinology, University Hospital Policlinico Consorziale
About the Expert
Prof. Francesco Giorgino, MD
President, Italian Society of Endocrinology (SIE)
Professor of Endocrinology, Chairman, Department of Emergency and Organ Transplantation
Head, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases
University of Bari Aldo Moro
Chief, Division of Endocrinology, University Hospital Policlinico Consorziale
Francesco Giorgino is Professor of Endocrinology and Metabolism and Chairman of the Department of Emergency and Organ Transplantation at the University of Bari Aldo Moro, Bari, Italy. He is also Chief of the Division of Endocrinology at the University Hospital Policlinico Consorziale in Bari, Italy.
Professor Giorgino has received distinguished scientific awards from various international and national institutions, and he has served on many national commissions and national boards, including the Executive Committees and Scientific Committees of the Italian Society of Diabetology and of the Italian Society of Endocrinology. He is currently President of the Italian Society of Endocrinology.
He is or has been a member of the Editorial Boards for the following journals: PLoS ONE, Journal of Endocrinology, Endocrinology, Journal of Endocrinological Investigation, Adipocyte, Acta Diabetologica, Cardiorenal Medicine, and Diabetes Metabolism Research and Reviews. He has published more than 200 original and review articles in prestigious scientific journals and has been an invited speaker at many national and international meetings.
Professor Giorgino’s research interests include the mechanisms leading to insulin resistance and beta-cell dysfunction in type 2 diabetes with a particular focus on skeletal muscle metabolism and organ cross-talk, inflammation and lipotoxicity, and the effects of diabetes drugs on pancreatic islets and the cardiovascular system.
References
1. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008.
